ABSTRACT: Obesity (especially visceral adiposity) can be associated with 3 different phenotypes of heart failure: heart failure with a reduced ejection fraction, heart failure with a preserved ejection fraction, and high-output heart failure. All 3 phenotypes are characterized by an excessive secretion of aldosterone and sodium retention. In addition, obesity is accompanied by increased signaling through the leptin receptor, which can promote activation of both the sympathetic nervous system and the renin-angiotensin system and can directly stimulate the secretion of aldosterone. The deleterious interaction of leptin and aldosterone is potentiated by the simultaneous action of adiposity and the renal sympathetic nerves to cause overactivity of neprilysin; the loss of the counterbalancing effects of natriuretic peptides is exacerbated by an additional effect of both obesity and heart failure to interfere with adiponectin signaling. This intricate neurohormonal interplay leads to plasma volume expansion as well as to adverse ventricular remodeling and cardiac fibrosis. Furthermore, the activity of aldosterone and neprilysin is not only enhanced by obesity, but these mechanisms can also promote adipogenesis and adipocyte dysfunction, thereby enhancing the positive feedback loop. Last, in elderly obese women, changes in quantity and biology of epicardial adipose tissue further enhances the release of leptin and other proinflammatory adipokines, thereby leading to cardiac and systemic inflammation, end-organ fibrosis, and multiple comorbidities. Regardless of the phenotypic expression, activation of the leptin-aldosterone-neprilysin axis appears to contribute importantly to the evolution and progression of heart failure in people with obesity. Efforts to interfere with the detrimental interactions of this distinctive neurohormonal ecosystem with existing or novel therapeutic agents are likely to yield unique clinical benefits.
O besity is a major determinant of the risk of heart failure, independent of its associated with ischemic cardiac injury, [1] [2] [3] and both diet-induced weight loss and bariatric surgery can prevent the occurrence and ameliorate the severity of heart failure in patients with a markedly increased body mass index. 3, 4 Conversely, interventions that induce weight gain lead to an increased risk of heart failure, 5 and increased fat mass in patients with heart failure is associated with greater disability. 6 Despite their close relationship, the coexistence of obesity and heart failure does not yield uniform clinical features but instead can present as 3 phenotypes: heart failure with a preserved ejection fraction (HFpEF), heart failure with a reduced ejection fraction, and high-output heart failure. 3, 7, 8 
THE 3 PHENOTYPES OF HEART FAILURE IN PEOPLE WITH OBESITY
All 3 forms of heart failure in people with obesity are characterized by the overproduction of aldosterone, sodium retention, plasma volume expansion, and an increase in cardiac filling pressures and volumes. 3, [7] [8] [9] [10] [11] [12] [13] These features explain why patients with obesity are more responsive to diuretics than individuals who are not obese. 14 However, the consequences of hypervolemia may depend on the underlying capacity of the heart to respond to volume overload. Conceptually and clinically, there are 3 possibilities.
First, if the heart has not been injured and is capable of meaningful ventricular enlargement, obesity-related sodium retention and plasma expansion can lead to marked cardiac dilatation with normal systolic function. 8 The heart can accommodate and eject the greatly augmented volume of blood that it receives, resulting in a high-output state but with elevated cardiac filling pressures. 13, 15 Because the ventricles can adaptively enlarge and cardiomyocytes are stretched, circulating levels of natriuretic peptides are markedly increased, partially ameliorating the sodium retention but also leading to systemic vasodilatation. 8 This action limits the increases in blood pressure that would normally be expected to accompany a major expansion of plasma volume. These features characterize the high-output heart failure state that is associated with obesity.
Second, if systolic function is preserved but the distensibility of the heart is impaired because of inflammation or fibrosis, then sodium retention and plasma volume expansion lead to cardiac overfilling rather than cardiac dilatation. [16] [17] [18] [19] In these patients, central obesity is associated with increased levels of aldosterone and other adipokines, 10, 11, 20 as well as changes in the biology of visceral (particularly epicardial) fat. 7, 21, 22 The interplay of adipokines and epicardial adipose tissue can cause cardiac inflammation. 23 , 24 The resulting myocardial, pericardial, and vascular fibrosis leads to increased ventricular and aortic stiffness, [25] [26] [27] [28] explaining why cardiac chambers are only modestly enlarged in elderly people with obesity and also heart failure. 7, 19 Because cardiac stretch is limited, natriuretic peptides are not markedly increased, although cardiac filling pressures are meaningfully elevated. 7 As a result, aldosteronemediated sodium retention and plasma volume expansion continue without the counterbalancing effects of natriuretic peptides. 7, [10] [11] [12] The risk of atrial tachyarrhythmias is exacerbated by the presence of epicardial fat and cardiac fibrosis. 29, 30 This framework explains why abdominal obesity increases the risk of death in patients with HFpEF, 31 why mineralocorticoid receptor signaling aggravates adverse shifts in adipocyte biology, 32 why mineralocorticoid receptor antagonists ameliorate experimentally induced obesity-related heart failure, 33 why spironolactone is particularly effective in reducing morbidity and mortality in patients with obesity with HFpEF, 34 and why patients with HFpEF respond most favorably to inhibitors of aldosterone secretion and action when they have only modestly increased levels of natriuretic peptides. 35, 36 These features are hallmarks of obesity-related HFpEF. 7 Third, heart failure and a reduced ejection fraction can occur in people with obesity. Obesity is often associated with a mild decrease in systolic function, which improves after weight loss. 3, 9, 13, 37, 38 However, if regional or global wall motion is substantially impaired because of an unrelated irreversible injury to the myocardium, adiposity adds to the pathophysiological burden. Obesity aggravates the activation of the sympathetic nervous and renin-angiotensin systems that are already present in these patients. 39 Visceral adiposity can cause systemic inflammation and cardiac fibrosis, thus exacerbating myocardial dysfunction. [40] [41] [42] Hyperaldosteronism related to obesity promotes sodium retention, augments cardiac filling pressures, aggravates remodeling, and accelerates the progression of heart failure. 43, 44 These actions may explain why, in patients with heart failure and impaired systolic function, those with central obesity are particularly likely to experience a reduction in morbidity and mortality with eplerenone. 45 These features characterize heart failure with a reduced ejection fraction in people with obesity.
PATHOPHYSIOLOGICAL LINKS BETWEEN OBESITY AND HEART FAILURE
How does adiposity contribute to these 3 distinct phenotypes of heart failure? It has long been assumed that the burden of obesity is a mechanical one (ie, if a heart is challenged to deliver sufficient peripheral levels of oxygen to move a patient with obesity through space, such an augmented demand (if extreme and prolonged) could cause ventricular enlargement and heart failure). Relief of the physical burden of obesity has been postulated to explain why bariatric surgery improves systolic function and prevents heart failure. 4, 46, 47 However, adipose tissue imposes a physical burden, and therefore adipocytes have important endocrine functions. Many effects of obesity are mediated through the secretion of adipokines-cell-signaling molecules that are associated with central obesity and visceral fat. [48] [49] [50] [51] [52] [53] Among the most prominent of these is leptin, which was originally identified and characterized by its actions on the hypothalamus to promote satiety. 54 Leptin plays a critical role in mediating the balance between energy demand and supply. When adipocytes are overfilled with lipids, they release leptin, which serves to reduce food intake and increase energy expenditure. 55, 56 The latter action is maintained in patients with heart failure. 56, 57 Could the interplay of leptin with other adipokines have a role in the 3 phenotypes of obesity-related heart failure?
DECIPHERING A ROLE FOR LEPTIN IN PEOPLE WITH OBESITY WITH HEART FAILURE
Alterations in leptin signaling can have profound effects on the heart. 58 Defects in the genes for leptin or its receptor in murine models lead to disturbed metabolism of cardiomyocytes, lipid accumulation in the myocardium, and cardiac dysfunction. [59] [60] [61] Experimentally, a reduction in leptin signaling impairs myocardial adaptability to stress. [62] [63] [64] Conditional knockout of leptin in a cardiomyocyte-specific manner leads to fulminant heart failure, 65, 66 and leptin improves the ability of hearts to respond to ischemia and pressure overload. 62, 66 However, it is difficult to extrapolate from observations in mice that have a genetic defect in leptin signaling to patients who have diet-related obesity in the clinical setting. Patients with obesity typically have elevated circulating levels of leptin and are resistant to its critical actions within the central nervous system to suppress food intake. 67 Yet this leptin resistance is selective. 68, 69 Chronic hyperleptinemia and obesity blunt the actions of leptin that are mediated by nitric oxide and are conventionally regarded as adaptive (ie, its ability to dilate blood vessels, promote natriuresis in the kidney, and decrease the contractile state of cardiomyocytes). [70] [71] [72] [73] [74] [75] [76] [77] [78] In contrast, the directionally opposite and maladaptive actions of the adipokine are sustained in states of selective leptin resistance, including its effects to stimulate the sympathetic nervous and renin-angiotensin systems, enhance sodium retention by the kidneys, and cause remodeling in the heart. [79] [80] [81] [82] [83] [84] [85] Therefore, the short-term actions of leptin in healthy individuals to lower blood pressure and shield cardiomyocytes from stimulation are transformed into actions that cause hypertension and adverse cardiovascular effects when the effects of leptin are maintained for long periods. 68, 69 The secretion of leptin by adipocytes appears to be a major driver of neurohormonal activation in obesity. [83] [84] [85] Leptin not only stimulates adrenergic-and angiotensindependent mechanisms, but this adipokine (rather than angiotensin II) may also be the major stimulus to the production of aldosterone in obesity 86, 87 and, thus, may be responsible for the excessive mineralocorticoid receptor signaling that is the hallmark of obesity-related heart failure.
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MODULATION OF LEPTIN IN PATIENTS WITH HEART FAILURE
The continued responsiveness of patients with obesity to the peripheral actions of leptin is important because the heart is replete with leptin receptors, and cardiomyocytes can secrete leptin that may act in an autocrine manner. 88 People who carry mutations in leptin-related genes have a markedly increased risk of both obesity and heart failure. 89, 90 Circulating levels of leptin predict the development of heart failure in elderly individuals [91] [92] [93] [94] and fully account for the influence of obesity to increase the risk of heart failure. 92 It important to note that in patients with heart failure, circulating levels of both leptin and soluble leptin receptor are markedly elevated. 20 The magnitude of the increases in serum leptin is correlated with symptom severity and exercise intolerance and is associated with clinical instability and an adverse prognosis. [95] [96] [97] [98] [99] [100] [101] The cardiac expression of leptin increases as the heart fails, and it subsides after ventricular unloading. 102 Further, circulating levels of leptin are elevated in heart failure independent of body mass index. 96, 98, 99, 101 These observations suggest that both adiposity and cardiac dysfunction may contribute to the hyperleptinemia seen in patients with obesity with heart failure.
Nevertheless, certain patients with heart failure have low levels of leptin-typically, those with cardiac cachexia. Low leptin levels are also occasionally seen in noncachetic patients who have markedly reduced their energy consumption. [103] [104] [105] Effective treatments for heart failure can reverse cardiac cachexia, 105, 106 especially if they interfere with the effects of β 2 -adrenergic receptors on energy expenditures. 107 As cachexia improves, levels of leptin increase as the mass of adipose tissue is restored. 105, 106, 108 However, in patients with obesity, the heightened levels of leptin appear to contribute to the genesis and progression of heart failure. Yet given the possibility of 3 distinct phenotypes, it has been challenging to understand how increased leptin receptor signaling might lead to different clinical states of heart failure. Recent studies have elucidated several important pathwaysparticularly in the kidneys and the heart-that may play an important role ( Figure 1 ).
ABNORMALITIES OF RENAL LEPTIN SIGNALING THAT PREDISPOSE TO HEART FAILURE
Obesity has long been known to cause sodium retention by the kidneys, 109 and the tubular mechanisms that mediate enhanced sodium reabsorption in overweight people have been identified: the epithelial sodium channel, Na+/K+-ATPases, and the thiazide-sensitive NaCl cotransporter. 110 Perhaps, as an adaptive response, other mechanisms of tubular sodium reabsorption are downregulated in obesity. 111 The primary stimulus of the epithelial sodium channel is aldosterone, which is excessively synthesized in both the adrenal gland and adipose tissue in people with obesity. 112, 113 The principal reason for the increase in Na+/K+-ATPase activity appears to be enhanced epidermal growth factor signaling, which plays a key role in the differentiation of adipocytes. 114, 115 Finally, the heightened activity of the Na+-Cl-cotransporter is likely related to increased trafficking through the renal sympathetic nerves, which (via the β 2 -adrenergic receptor) contributes importantly to sodium retention in obesity. [116] [117] [118] It is therefore intriguing that leptin has been shown to stimulate all 3 mechanisms that underlie the sodium tubular hyperreabsorption in people with obesity. Although the short-term administration of high doses of leptin increases sodium excretion, this transient effect is impaired in animals with dietary-induced obesity. 78 In contrast, long-term (and more moderate) elevations of plasma leptin (as is seen in obesity) impair renal sodium excretion. 82 Leptin enhances the secretion of aldosterone from the adrenal, both directly and indirectly, through the facilitation of angiotensin II. 85, 119 Furthermore, leptin acts both centrally and peripherally to stimulate the sympathetic nervous system (including enhancing catecholamine synthesis in the adrenal medulla), 84, 120, 121 which (in people with obesity) is channeled toward the renal sympathetic nerves. 116, 118, 122 Finally, leptin stimulates Na+/K+-ATPases 123 through transactivation of the epidermal growth factor receptor. 124, 125 Thus, leptin signaling mimics the precise mechanisms by which obesity leads to sodium retention and plasma volume expansion.
ABNORMALITIES OF CARDIAC LEPTIN SIGNALING THAT PREDISPOSE TO HEART FAILURE
The role of leptin in mediating sodium retention and plasma volume expansion is common to all 3 phenotypes of obesity-related heart failure. Therefore, if differences in the phenotypic expression are modulated by leptin, they may be related to distinctive interactions of leptin with the heart and neighboring tissues.
In patients whose ejection fraction is depressed, enhanced leptin action can contribute to heart failure by facilitating and mediating the activation of deleterious neurohormonal systems. By virtue of its direct actions on the central nervous system, leptin can fuel the sympathetic nervous and renin-angiotensin systems and accelerate the course of heart failure. 84, 85 This response appears to be particularly marked in women. 126, 127 Moreover, leptin-mediated increases in aldosterone may lead to sodium retention, plasma volume expan- Obesity is characterized by high circulating levels of aldosterone, which can be directly secreted by adipocytes or may be released from the adrenal gland in response to leptin. This latter action is potentiated by a loss of the antialdosterone action of natriuretic peptides that results from an increased neprilysin activity in obesity. Visceral adiposity also leads to increased signaling through the leptin receptor, which can cause sodium retention by a direct action on the renal tubules, an action to increase renal sympathetic nerve traffic, and stimulation of aldosterone. Leptin (released from epicardial adipose tissue and acting on adjacent tissues or released by dysfunctional fat and acting systemically) can promote inflammation, microcirculatory abnormalities, and fibrosis. Adiposity is also accompanied by increased activity of neprilysin, which is expressed on mature adipocytes and also released from the kidney in response to sympathetic nerve stimulation. The resulting deficiency of natriuretic peptides exacerbates the interaction of aldosterone and leptin to promote plasma volume expansion and regional and systemic inflammation and fibrosis. sion, and increased cardiac filling pressures. 119 Finally, by interacting with both angiotensin II and mineralocorticoid receptors and facilitating proinflammatory pathways, leptin can cause adverse cardiac hypertrophy and fibrosis. [128] [129] [130] [131] [132] [133] For all of these reasons, interference with leptin signaling has favorable effects on ventricular geometry, which are accompanied by the suppression of extracellular matrix remodeling. 129, 130, 133 In patients whose systolic function is preserved but whose hearts can adaptively dilate in response to plasma volume expansion, leptin can promote both the hypertrophy and elongation of cardiomyocytes and thereby facilitate eccentric ventricular remodeling. 134, 135 Changes in left ventricular mass are correlated with changes in leptin after bariatric surgery. 136 The action of leptin to promote eccentric hypertrophy may help to mediate the remarkable cardiac dilatation that typifies high-output heart failure in people with obesity. 8 However, if systolic function is preserved but distensibility is impaired (as in obesity-related HFpEF), then leptin can contribute to the limited capacity of the ventricle to dilate. First, leptin can adversely affect calcium handling in the heart so as to impair myocardial relaxation. 137, 138 Second, leptin may promote adverse aldosterone-mediated changes in ventricular geometry and stimulate the formation of the extracellular matrix and the synthesis of collagen, thus causing cardiac, pericardial, and vascular fibrosis. 119, 139, 140 Third, leptin is linked to the accumulation and dysfunctional biology of epicardial fat, 48, [141] [142] [143] which may directly lead to inflammation, microcirculatory abnormalities, and fibrosis of the underlying myocardium. 40, 144, 145 Changes in epicardial fat may explain the relationship between elevated levels of leptin and atrial tachyarrhythmias in HFpEF. 29, 30, 146, 147 It is interesting to note that these relationships may be sex-dependent; leptin is particularly increased (and its relationship to cardiac dysfunction is especially evident) in women, who are prone to HFpEF.
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OTHER ADAPTIVE AND MALADAPTIVE ADIPOKINES IN OBESITY AND HEART FAILURE
In addition to leptin, adipocytes secrete other cytokines that have proinflammatory actions (eg, tumor necrosis factor-α, interleukin-6, interleukin-1β, and resistin) and can contribute to the development of systolic dysfunction and cardiac fibrosis in experimental models. [150] [151] [152] [153] [154] [155] Circulating levels of these adipokines are increased in people with obesity and in patients with heart failure, and they are associated with increased disability, morbidity, and mortality. [156] [157] [158] [159] [160] [161] [162] [163] These proinflammatory cytokines may also participate in the renal responses to neurohormonal overactivity seen in obesity, and by enhancing the biological activity of adipocytes, they may promote the release of leptin. [164] [165] [166] [167] However, unlike leptin, they do not lead to an increase in aldosterone, which is a signature feature of heart failure in people with obesity. 168 This distinction may explain why antagonists of these adipokines have not favorably influenced the course of heart failure, at least in patients with a reduced ejection fraction. [169] [170] [171] Certain adipokine inhibitors may actually stimulate the release of aldosterone, 168 as do other agents that increase the risk of major adverse cardiovascular events in patients with metabolic abnormalities. 172 It is interesting to note that adipocytes also secrete adiponectin, which exerts adaptive physiological actions that would be expected to minimize the risk of heart failure. Adiponectin inhibits cardiac hypertrophy, inflammation, and fibrosis; [173] [174] [175] antagonizes the actions of endogenous vasoconstrictors (including the activity of renal sympathetic nerves); [175] [176] [177] [178] and promotes natriuresis (in part) by suppressing the secretion of aldosterone. 179, 180 Adiponectin also improves the ability of the heart to sustain a pressure or volume overload and protects the heart against both ischemic injury and oxidative stress. [181] [182] [183] [184] It is therefore noteworthy that, in contrast to other adipokines, obesity leads to a decrease in adiponectin gene expression (Figure 2) , 185, 186 which appears to be caused by obesity-related inflammation and the synthesis of proinflammatory cell-signaling molecules, including tumor necrosis factor, interleukin-6, and aldosterone. [187] [188] [189] [190] [191] Circulating levels of adiponectin are markedly reduced in people with obesity, including those with heart failure, [192] [193] [194] and adipokine levels are particularly low in women with obesity with elevated cardiac filling pressures and normal systolic function. [195] [196] [197] Volume overload further suppresses the release of adiponectin. 181 As loading conditions worsen, levels of adiponectin remain depressed as long as systolic function is preserved. 181, 198, 199 This decline in adiponectin is likely to be pathophysiologically important; experimentally, adiponectin gene deletion aggravates cardiac remodeling in response to pressure overload, 200 whereas adiponectin repletion prevents the progression of aldosterone-induced volume overload, cardiac hypertrophy, fibrosis, and ventricular filling abnormalities. 201, 202 Furthermore, obesity or a high-fat diet may induce resistance to adiponectin's adaptive biological actions. [203] [204] [205] Thus, both increases in leptin and a deficiency in adiponectin signaling likely contribute to obesity-related HFpEF.
However, when heart failure is accompanied by a reduced ejection fraction, circulating levels of adiponectin are increased, although the primary source may not be adipose tissue. The heart has its own paracrine adiponectin system, which is downregulated in and may contribute to the development of experimental and clinical dilated cardiomyopathy. [206] [207] [208] However, as systolic function declines over time, adiponectin is released from the myocardium, 209 and as heart failure advances, circulating levels of adiponectin become progressively elevated, particularly in those with reduced muscle mass and cachexia, and are indicative of a poor prognosis. [210] [211] [212] [213] In such patients, levels of adiponectin decrease after effective treatment, but progressive increases in the adipokine despite therapy are associated with an increased risk of death. 192, 194, 214, 215 The high levels of natriuretic peptides in these patients may be the primary stimulus to the secretion of adiponectin. [216] [217] [218] [219] However, despite elevated levels, the adipokine may not be able to exert its expected physiological benefits in advanced heart failure because such patients are resistant to its actions, possibly as a result of receptor downregulation. 97, 216 It is interesting to note that prolonged ventricular unloading in patients with end-stage heart failure partially restores adiponectin receptors and responsiveness. 97 
POTENTIAL INTERACTIONS OF LEPTIN AND NEPRILYSIN IN HEART FAILURE
Neprilysin is responsible for the degradation of endogenous natriuretic peptides that have important adaptive cardiovascular effects, including direct effects to inhibit the renal sodium reabsorption, suppress the secretion of aldosterone from the adrenal gland, [221] [222] [223] and inhibit cardiac inflammation and fibrosis (Figure 2) . 167, 224, 225 Levels of neprilysin are increased in chronic heart failure, rise further during acute decompensation, and are associated with an adverse outcome in patients with a reduced ejection fraction. [226] [227] [228] Neprilysin inhibition has favorable effects on cardiac remodeling 224, 229, 230 and reduces the morbidity and mortality of patients with heart failure with impaired systolic function. 231 Although not typically regarded as an adipokine, neprilysin is expressed on the surface of mature adipocytes, 232, 233 which presumably shed the enzyme into the plasma where its soluble form can be measured. Intake of a high-fat diet increases circulating levels of neprilysin, and visceral fat contains high levels of the enzyme. [233] [234] [235] Additionally, the enhanced renal sympathetic nerve activity that characterizes patients with obesity leads to activation of neprilysin within the kidney. 167 People with obesity have increased levels of neprilysin in proportion to their body mass, 234, 235 and circulating levels of soluble neprilysin are particularly elevated in patients with obesity with HFpEF. 236 The action of adipocyte-derived neprilysin likely explains why levels of B-type natriuretic peptide are low in patients with central obesity, particularly those with substantial quantities of epicardial fat; 28, 237 why the breakdown of infused B-type natriuretic peptide is accelerated in patients with HFpEF; 238 why levels of B-type natriuretic peptide (which is a substrate for neprilysin) are disproportionately lower than levels of N-terminal B-type natriuretic peptide (which is not a substrate for neprilysin) in people with obesity; 239 why the measurement of natriuretic peptides may be misleading in patients with obesity with heart failure (especially those with HFpEF); [240] [241] [242] and why levels of B-type natriuretic peptide increase after bariatric surgery. 243 It is important to note that neprilysin inhibition decreases ventricular overload and ameliorates left atrial overfilling in patients with HFpEF who are obese. 244 Adipocytes secrete neprilysin that acts to degrade natriuretic peptides, whereas B-type natriuretic peptides have direct effects on adipocyte function to stimulate both lipolysis and adipocyte differentiation in a manner that would be expected to limit adiposity. [245] [246] [247] Therefore, adipocytes synthesize neprilysin, and nepri- The adverse effects of leptin and aldosterone to cause sodium retention, potentiate neurohormonal activation, and promote cardiac inflammation and fibrosis are normally held in check by endogenous mechanisms (ie, adiponectin and natriuretic peptides). However, adiponectin receptor signaling is attenuated in patients with obesity with heart failure, in part, because obesity causes a decrease in circulating adiponectin levels and, in part, because heart failure leads to adiponectin resistance. Additionally, the expected effect of natriuretic peptides to stimulate adiponectin is attenuated as a result of increased neprilysin activity. Heart failure may also promote leptin receptor signaling, possibly related to the secretion of leptin from cardiomyocytes in the failing heart. Enhanced mineralocorticoid receptor signaling (together with the relative loss of natriuretic peptides) can augment adipogenesis and adipose tissue dysfunction. lysin promotes adipogenesis. 234 This positive feedback loop suggests that the overactivity of neprilysin can potentially lead to obesity and, thus, to the secretion of leptin. 248 Circulating levels of leptin are inversely correlated with those of natriuretic peptides. 48 Such an inverse relationship might have evolutionary advantages because both leptin and B-type natriuretic peptide act to suppress hunger and promote satiety. 249, 250 It is noteworthy that many of the actions of natriuretic peptides on the heart and kidneys are opposite to those of leptin (ie, whereas leptin promotes sodium retention, adverse cardiac remodeling, and myocardial inflammation and fibrosis, endogenous natriuretic peptides increase urinary sodium excretion, exert favorable effects on ventricular geometry, and inhibit inflammatory and fibrotic processes in the heart). 119, 133, 251, 252 The 2 pathways appear to interact at multiple levels to maintain balance between them. [253] [254] [255] [256] [257] [258] Accordingly, any overactivity of neprilysin removes a major counterbalancing mechanism that would normally be positioned to limit the impact of deranged leptin receptor signaling to cause important pathophysiological abnormalities.
Because angiotensin II is a substrate for neprilysin, 259 neprilysin inhibition is necessarily prescribed together with angiotensin receptor antagonism in clinical practice. 231, 241 Furthermore, although leptin may diminish neprilysin and its ability to degrade β-amyloid in astrocytes, 260 this finding appears irrelevant to obesity because the neurocognitive deficits seen in obesity are not related to increased leptin signaling or β-amyloid deposition. 261 Instead, neprilysin inhibition is associated with increased signaling through the glucagon-like peptide-1 receptor, which decreases the accumulation of and the inflammatory response to β-amyloid. 262 In obesity, the action of leptin to augment renal sympathetic nerve traffic and the release of neprilysin from the kidney 167 explains why adiposity is associated with increased activity of both adipokines. The action of neprilysin to accelerate natriuretic peptide degradation potentiates the consequences of increased leptin signaling.
ROLE OF EPICARDIAL FAT IN THE INTERPLAY OF ADIPOKINES AND HEART FAILURE
The human heart is surrounded by 2 different depots of adipose tissue: epicardial adipose tissue resides between the myocardium and the visceral layer of pericardium, whereas pericardial adipose tissue is located between visceral and parietal pericardium. There is no distinct anatomic boundary between epicardial fat and the underlying myocardium; the 2 share an unobstructed microcirculation, which allows adipokines and mesenchymal cells produced in epicardial adipose tissue to migrate to and influence the neighboring muscle. 263 Furthermore, epicardial fat has a distinctive transcriptome, 264 which (when healthy) nourishes the heart but (with increasing body mass) shifts to molecular pathways that promote the synthesis of proinflammatory adipokines. [263] [264] [265] [266] [267] When compared with other visceral fat deposits, epicardial adipose tissue is unusually biologically active, 268 thus explaining why its accumulation is associated with cardiovascular risk. 269, 270 It is important to note that the altered biology of epicardial fat is accompanied by increased levels of leptin, 48, 141, 268, 270, 271 and the close relationship between epicardial adiposity and abdominal obesity may explain the ability of leptin measurements to predict the risk of heart failure. 92, 272, 273 The quantity and biology of epicardial fat is likely to be a critical determinant of the phenotype produced by activation of the leptin-aldosterone-neprilysin axis in people with obesity with normal systolic function (Figure 3) . Patients with obesity with high-output heart failure are typically younger and healthier than those with obesity-related HFpEF, 7, 8 and these features may explain why their ventricles can dilate appropriately in response to volume overload. By contrast, patients with obesityrelated HFpEF are generally elderly women with a metabolic syndrome, who characteristically have changes in the quantity and biology of epicardial adipose tissue and exhibit local inflammation of the adjoining myocardium and systemic inflammation involving visceral organs, 7, 158, 193, [274] [275] [276] [277] and in whom the accumulation of epicardial fat is associated with abnormalities of cardiac dynamics and diastolic filling. [278] [279] [280] [281] It is intriguing that both aging and the female sex are also accompanied by heightened levels of aldosterone, leptin, and nepri- lysin; an increase in renal sympathetic activity; and a decrease in the counterbalancing effects of adiponectin and endogenous natriuretic peptides. [282] [283] [284] [285] [286] [287] [288] [289] Moreover, once the leptin-aldosterone-neprilysin axis is activated, sustained increases in aldosterone and neprilysin may further promote the accumulation and inflammation of epicardial fat. 32, 234, 290 Mineralocorticoid receptor antagonists and neprilysin inhibitors may exert their effects in obesity-related HFpEF, in part, by mitigating adiposityrelated dysfunction and adipogenesis. [165] [166] [167] 291, 292 On a local level, biologically active epicardial adipose tissue releases proinflammatory adipokines that can adversely affect both the structure and function of the underlying myocardium, 266, 267 and it can also act as a reservoir for mesenchymal stem cells that can migrate to the neighboring muscle and be transformed into fibroblasts. 143, 293 In addition, epicardial fat contributes to the heightened levels of leptin in the general circulation, leading to systemic inflammation, 42, 294 which can adversely affect visceral organs other than the heart. Elevated levels of leptin can promote inflammatory processes in the kidney, 295, 296 thus explaining the renal fibrosis seen in experimentally induced obesity-related HFpEF. 297 High circulating levels of leptin are accompanied by an accelerated rate of decline in renal function (particularly in women), 298, 299 potentially explaining why the glomerular filtration rate in patients with obesityrelated HFpEF is half that seen in patients with obesity with high-output heart failure. 7, 8 Increased leptin signaling can also cause pulmonary and hepatic fibrosis. [300] [301] [302] [303] For all of these reasons, leptin-mediated systemic inflammation and fibrosis may explain the frailty and multiple comorbidities that are characteristic of patients with HFpEF 303, 304 and why abdominal obesity increases the risk of noncardiovascular death in HFpEF. 31 It is interesting to note that patients with obesity with diabetes mellitus are particularly likely to have increased and dysfunctional epicardial adipose tissue. 142, 305 Antihyperglycemic medications that cause weight loss (eg, glucagon-like peptide-1 agonists, dipeptidyl peptidase-4 inhibitors, and sodium-glucose cotransporter 2 inhibitors) act to reduce the quantity of epicardial fat, [306] [307] [308] [309] but they may exert different effects on its biology, and thus its release of leptin, acting in a paracrine manner on adjacent tissues. Sodium-glucose cotransporter 2 inhibitors reduce adiposity-related inflammation and dysfunction, whereas glucagon-like peptide-1 receptor signaling may aggravate adipocyte dysfunction, and dipeptidyl peptidase-4inhibitors may cause cardiac fibrosis by potentiating proinflammatory chemokines. [310] [311] [312] [313] [314] These different actions on adipose tissue are noteworthy because sodium-glucose cotransporter 2 inhibitors (but not glucagon-like peptide-1 receptor agonists) reduce the risk of heart failure events in patients with type 2 diabetes mellitus, who are likely to develop obesity-related HFpEF. [315] [316] [317] [318] In contrast, the risk of heart failure hospitalizations in these patients is increased with dipeptidyl peptidase-4 inhibitors.
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CONCLUSIONS
Heart failure in people with obesity is characterized by a triad of neurohormonal abnormalities-specifically, an excess secretion of aldosterone, increased signaling through the leptin receptor pathway, and overactivity of neprilysin leading to a relative deficiency of endogenous natriuretic peptides. The interplay of these 3 mechanisms contributes importantly to the sodium retention and plasma volume expansion, the activation of both the sympathetic nervous and renin-angiotensin systems, and the adverse ventricular remodeling and cardiac fibrosis that are seen in people with obesity who have heart failure. These interactions are pathophysiologically relevant in patients with obesity, whether the specific phenotype is heart failure with a reduced ejection fraction, HFpEF, or high-output heart failure. The actions of leptin on the kidney closely mirror the derangements seen in obesity-related sodium retention, and the action of the adipokine may be causally responsible for the major role played by aldosterone and the renal sympathetic nerves in enhancing renal tubular sodium reabsorption in patients with obesity. Leptin may contribute to plasma volume expansion as well as the eccentric ventricular dilatation and hypertrophy that is seen in high-output states, and an increase in leptin signaling as a result of aging and the accumulation and inflammation of epicardial fat may cause myocardial fibrosis (and thus limit cardiac distensibility) and provoke the atrial tachyarrhythmias seen in patients with obesity-related HFpEF. The pathophysiological consequences of leptin overactivity may become particularly important if the ability of natriuretic peptides to physiologically oppose the actions of leptin is limited by enhanced neprilysin activity and if both visceral adiposity and heart failure impair adiponectin receptor signaling. Furthermore, aldosterone and neprilysin are not only secreted by adipocytes, but they also promote adipogenesis, adipocyte dysfunction, and adipose tissue inflammation, thereby enhancing the positive feedback loop.
Regardless of the specific phenotypic expression, activation of the leptin-aldosterone-neprilysin axis is likely to contribute meaningfully to the evolution and progression of heart failure in people with obesity. The conceptualization and presentation of this new framework offers an opportunity to evaluate its merits, modify its elements, or (potentially) reject the hypothesis altogether. However, if the importance of this sodiumretaining and proinflammatory adipocyte-based neurohormonal system is validated by future experimental and clinical studies, efforts to modulate this axis with existing or novel therapeutic agents are warranted and may yield unique benefits. 
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